N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
Subscribe To Our Newsletter & Stay Updated
